Navigation Links
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.

"The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper , M.D., executive vice president of Research and Development at Amgen. "As a company rooted in biology, we are in a strong position to develop innovative therapies that fight cancer through new pathways such as immunotherapy and to leverage biomarkers to advance personalized medicine."

Meeting delegates who visit Amgen's booth will also have the opportunity to learn more about Amgen's legacy of manufacturing expertise – from research and development to delivery of complex biological therapies.

Abstracts are currently available on the ASCO website at http://abstract.asco.org/.

ABSTRACTS OF INTEREST INCLUDE:

Talimogene Laherparepvec
The results of the primary analysis of the pivotal trial of talimogene laherparepvec, an investigational oncolytic immunotherapy for the treatment of melanoma, including interim overall survival data, will be presented. 

  • OPTiM: A Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) versus Subcutaneous (SC) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment (tx) of Unresected Stage IIIB/C and IV Melanoma
    Abstract No. LBA9008, Oral Presentation, Saturday, June 1, 3:45 p.m. CDT, S406

Blinatumomab
Results from a Phase 1 study
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
2. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
3. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
4. Amgen Announces Webcast of 2013 First Quarter Financial Results
5. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
6. Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
7. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
8. Selexis Announces Expansion of R&D License Agreement with Amgen
9. Amgen Outlines Long-Term Strategy
10. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
11. Amgen To Webcast 2013 Business Review Meeting On February 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Research Solutions, Inc. (OTCQB: ... and medical (STM) information for life science companies, academic ... to present at the LD Micro Invitational being held ... in Los Angeles . ... on Wednesday, June 3rd at 9:30 a.m. Pacific time, ...
(Date:6/1/2015)...  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... ,nal-IRI, in a Phase 1 investigator-sponsored study at the ... were presented at the 2015 American Society of Clinical ... Results from this study show a tolerable ... when given intravenously.  Based in part on ...
(Date:6/1/2015)... 2015 About Pressure Relief ... area and improve the quality life of patients who ... play a significant role in inhibiting the growth and ... to turn or rotate an immobile patient by providing ... overlay, and specialty beds. These devices have the ability ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3
... , SAN DIEGO, Oct. 6 NuVasive, Inc. (Nasdaq: ... for minimally disruptive surgical treatments for the spine, announced details ... will take place on Tuesday, October 20, 2009, after the ... conference call on Tuesday, October 20, 2009, at 5:30 p.m. ...
... 6 Physiotherapy Associates, the nation,s foremost provider ... free educational brochure on the benefits of physical ... Physical Therapy Month," as designated by the American ... offers Physiotherapy Associates, 1,500 clinicians a way to ...
Cached Medicine Technology:NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results 2NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results 3Physiotherapy Associates Marks 'National Physical Therapy Month' With Free Educational Brochure 2
(Date:6/2/2015)... ODU , a worldwide ... solutions and cable assemblies, is announcing its highly ... US market. , ODU MINI-SNAP® is ... self- securing circular connector solution is ideal for ... significant customization such as: sensor devices, data collecting ...
(Date:6/2/2015)... PhishLine, LLC today announced it ... Drive, Suite 125 in Waukesha, Wisconsin 53186. ... base of operations for PhishLine’s current corporate staff ... , Mark Chapman, Founder and President, commented “PhishLine ... enterprise customers adopt our market leading service to ...
(Date:6/2/2015)... 2015 The Non-GMO Project offers ... made according to rigorous best practices for GMO ... in compliance with the Non-GMO Project Standard - ... ingredients, facility inspections and an annual audit to ... , “Savoury Systems is and has always been ...
(Date:6/2/2015)... TheCelebrityDresses.com, a popular online store selling celebrity inspired ... fashion cocktail dresses. The company carries more than 1000 ... suitable for a wide variety of summer events like ... make high quality trendy special occasion dresses ... satin, chiffon and cotton. Their products feature a wide ...
(Date:6/2/2015)... 02, 2015 TranSlice: Reveal from Pixel Film ... TranSlice: Reveal allows Final Cut Pro X users to transition ... reveal their next screen. , TranSlice Reveal brings back the ... Cut Pro X users can now transition from one ... With every panel orientation and direction covered, no transition will ...
Breaking Medicine News(10 mins):Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2
... Senator Norm Coleman, Deputy HHS Secretary Tevi ... patient and medical community participate in a conference to, ... Preventive, Services Task Force report dismissing the vital role ... The Potomac,Institute for Policy Studies and the Glaucoma Foundation ...
... Although all cancers are not alike, most share common ... mutation or faulty biochemical signaling pathway. For that reason, ... impact on many others. Increasingly, researchers are discovering ways ... broadening the targets of already-approved targeted therapeutics. ...
... for more accurately determining the composition of medicines. ... techniques that were previously considered to be incompatible: ... detection technique mass spectroscopy (MS). He has used ... mechanism for the active ingredient and excipients in ...
... fool Mother Nature, experts say , , WEDNESDAY, Oct. 24 (HealthDay ... an hour more of sunlight, but it appears that their ... researchers report. , In fact, daylight savings time can cause ... our bodies, according to the report in the Oct. 24 ...
... Oct. 24 In a pioneering effort, Children,s,Hospital ... Pittsburgh School of,Medicine have joined forces to launch ... field of pediatric research. The potential of ... Mellon Foundation through a groundbreaking gift of $23 ...
... of ... ARLINGTON, Va., Oct. 24 Vangent, Inc., a leading,provider ... leading expert in governmental healthcare programs and member,eligibility, today ... services to redeem members who recently received letters,from the ...
Cached Medicine News:Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 2Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 3Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 4Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 6Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 7Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 8Health News:New technique improves purity of medicines 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 3Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 2Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 2Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 4
... The Monarc Subfascial Hammock™ is ... female patients suffering from stress urinary ... by supporting the urethra during abdominal ... or laughing. Monarc's outside-to-in transobturator approach ...
... innovative architecture of the Uretex® ... and integrity for tension-free sling ... anchors securely to surrounding tissue ... alternate fixation devices, minimizing risk ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: